TandemAI and Perpetual Medicines Announce Strategic Merger to Expand Physics and AI-Based Drug Discovery Capabilities
TandemAI, a company transforming drug discovery with state-of-the-art AI and physics-based technologies integrated with full wet lab capabilities, and Perpetual Medicines, which is advancing a computational design-synthesis platform for peptide drug discovery today announced the companies have merged. The combined company, to be known as TandemAI, will provide partners with an expanded range of methods and workflows for both small molecule and peptide drug discovery and bring additional leadership with an extensive track record in drug discovery and development.
TandemAI Announces the Release of TandemViz™ 1.0 Web-based Graphical User Interface for Seamless Integration of Computational Analyses and Experimental Data
TandemAI today announced the release of TandemViz™ 1.0, the company’s proprietary web-based platform that provides its growing roster of drug discovery clients with a user-friendly and collaborative graphical interface to TandemAI’s suite of computational tools. The platform, which can be accessed from anywhere through a web browser without the need to install any software locally, allows the seamless integration and visualization of experimental data alongside computational analyses.
TandemAI Raises $35 Million in Series A Financing to Expand Integrated Computational and Wet Lab Solutions to Accelerate Drug Discovery
TandemAI, a technology company focused on transforming drug discovery infrastructure, today announced it has raised $35 million in a Series A financing to expand its drug discovery service platform that integrates breakthrough computational tools with wet lab biophysics, medicinal chemistry, and biology. Qiming Venture Partners led the financing along with participation from OrbiMed, Eight Roads Ventures, and F Prime Capital.
TandemAI Announces Appointment of Alessandro Monge, Ph.D., as Chief Business Officer
TandemAI, a technology company focused on transforming drug discovery infrastructure, today announced the appointment of Alessandro Monge, PhD, as Chief Business Officer. Dr. Monge has more than 20 years of experience in developing and deploying marketing strategies for computational technologies at established companies such as Schrödinger, as well as emerging companies, most recently at Iktos, where he was Senior Vice President and Head of US Operations.
TandemAI Announces Appointment of Steve Swann, Ph.D., as Chief Scientific Officer
TandemAI today announced the appointment of Steve Swann, Ph.D., to the newly created position of Chief Scientific Officer. Dr. Swann joins TandemAI with nearly 20 years of research and research leadership experience in medicinal and computational chemistry at large and emerging pharmaceutical companies, most recently at Exscientia, where he was Vice President of Medicinal Chemistry (US).
TandemAI Announces Expansion of Senior Leadership Team
TandemAI, a technology company focused on transforming drug discovery infrastructure, today announced two key appointments to its senior leadership team. Albert Pan, Ph.D., has joined the company as Chief Technology Officer and Lanny Sun, Partner and Chief Investment Officer of Gordian Ventures, has joined the board and been named Chairman of the Board of Directors.
TandemAI Announces $25 Million Seed & Pre-series A Financing Led by OrbiMed and Chengwei Capital
TandemAI today announced it has raised $25 million in Seed and pre-Series A financing to advance its proprietary computational platform and expansion of its wet lab operations. The company will tightly integrate the computational platform with wet labs for biophysics, medicinal chemistry, and biology in order to accelerate the design and optimization of drug candidates for partners. The round was led by OrbiMed and Chengwei Capital.
